Ambeed.cn

首页 / / / / SU11652

SU11652 {[allProObj[0].p_purity_real_show]}

货号:A581825 Ambeed 开学季,买赠积分,赢豪礼

SU11652 is a sunitinib analog with anti-tyrosine-kinase activity, also is identified as a potential inhibitor for Leishmania major (Lm) nucleoside diphosphate kinases NDK and structural studies indicated that this molecule binds to the active site of LmNDK in a similar conformation to nucleotides, mimicking natural substrates.

SU11652 化学结构 CAS号:326914-10-7
SU11652 化学结构
CAS号:326914-10-7
SU11652 3D分子结构
CAS号:326914-10-7
SU11652 化学结构 CAS号:326914-10-7
SU11652 3D分子结构 CAS号:326914-10-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

SU11652 纯度/质量文件 产品仅供科研

货号:A581825 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 VEGFR1 VEGFR2 VEGFR3 其他靶点 纯度
Motesanib Diphosphate ++++

VEGFR1, IC50: 2 nM

++++

VEGFR2/Flk1, IC50: 3 nM

VEGFR2, IC50: 3 nM

+++

VEGFR3, IC50: 6 nM

RET,PDGFR {[allProObj[0].p_purity_real_show]}
Tivozanib ++

VEGFR1, IC50: 30 nM

+++

VEGFR2, IC50: 6.5 nM

++

VEGFR3, IC50: 15 nM

{[allProObj[0].p_purity_real_show]}
Brivanib +

VEGFR1, IC50: 380 nM

++

VEGFR2, IC50: 25 nM

Flk1, IC50: 25 nM

{[allProObj[0].p_purity_real_show]}
Regorafenib +++

VEGFR1, IC50: 13 nM

+++

VEGFR2, IC50: 4.2 nM

+

VEGFR3, IC50: 46 nM

RET {[allProObj[0].p_purity_real_show]}
Pazopanib +++

VEGFR1, IC50: 10 nM

++

VEGFR2, IC50: 30 nM

+

VEGFR3, IC50: 47 nM

c-Kit,FGFR,PDGFR {[allProObj[0].p_purity_real_show]}
Sitravatinib +++

VEGFR1 (FLT1), IC50: 6 nM

+++

VEGFR2 (KDR), IC50: 5 nM

++++

VEGFR3 (FLT4), IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
Foretinib +++

VEGFR1/FLT1, IC50: 6.8 nM

++++

KDR, IC50: 0.86 nM

++++

VEGFR3/FLT4, IC50: 2.8 nM

Tie-2 {[allProObj[0].p_purity_real_show]}
MGCD-265 analog ++++

VEGFR1, IC50: 3 nM

++++

VEGFR2, IC50: 3 nM

++++

VEGFR3, IC50: 4 nM

Tie-2 {[allProObj[0].p_purity_real_show]}
Lactate +++

VEGFR1/FLT1, IC50: 10 nM

+++

VEGFR2/Flk1, IC50: 13 nM

+++

VEGFR3/FLT4, IC50: 8 nM

c-Kit,FLT3 {[allProObj[0].p_purity_real_show]}
AEE788 +

FLT1, IC50: 59 nM

+

KDR, IC50: 77 nM

EGFR {[allProObj[0].p_purity_real_show]}
Linifanib ++++

VEGFR1/FLT1, IC50: 3 nM

++++

VEGFR2/KDR, IC50: 4 nM

+

VEGFR3/FLT4, IC50: 190 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Vatalanib 2HCl +

VEGFR1/FLT1, IC50: 77 nM

++

VEGFR2/Flk1, IC50: 270 nM

VEGFR2/KDR, IC50: 37 nM

+

VEGFR3/FLT4, IC50: 660 nM

c-Kit,c-Fms {[allProObj[0].p_purity_real_show]}
Axitinib ++++

VEGFR1/FLT1, IC50: 0.1 nM

++++

VEGFR2/Flk1, IC50: 0.18 nM

VEGFR2/KDR, IC50: 0.2 nM

{[allProObj[0].p_purity_real_show]}
Dovitinib +++

VEGFR1/FLT1, IC50: 10 nM

+++

VEGFR2/Flk1, IC50: 13 nM

+++

VEGFR3/FLT4, IC50: 8 nM

c-Kit,FLT3 {[allProObj[0].p_purity_real_show]}
ZM 306416 +

VEGFR1, IC50: 0.33 μM

Src {[allProObj[0].p_purity_real_show]}
KRN-633 +

VEGFR1, IC50: 170 nM

+

VEGFR2, IC50: 160 nM

+

VEGFR3, IC50: 125 nM

c-Kit,BTK {[allProObj[0].p_purity_real_show]}
OSI-930 +++

FLT1, IC50: 8 nM

+++

KDR, IC50: 9 nM

{[allProObj[0].p_purity_real_show]}
Lenvatinib ++

VEGFR1/FLT1, IC50: 22 nM

++++

VEGFR2/KDR, IC50: 4.0 nM

+++

VEGFR3/FLT4, IC50: 5.2 nM

{[allProObj[0].p_purity_real_show]}
NVP-BAW2881 +

hVEGFR1, IC50: 820 nM

+++

hVEGFR2, IC50: 9 nM

mVEGF2, IC50: 165 nM

+

hVEGFR3, IC50: 420 nM

{[allProObj[0].p_purity_real_show]}
Cediranib +++

VEGFR1/FLT1, IC50: 5 nM

++++

VEGFR2/KDR, IC50: 0.5 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Nintedanib ++

VEGFR1, IC50: 34 nM

+++

VEGFR2, IC50: 13 nM

+++

VEGFR3, IC50: 13 nM

FLT3 {[allProObj[0].p_purity_real_show]}
BMS-794833 ++

VEGFR2, IC50: 15 nM

{[allProObj[0].p_purity_real_show]}
SKLB1002 ++

VEGFR2, IC50: 32 nM

{[allProObj[0].p_purity_real_show]}
Cabozantinib S-malate ++++

VEGFR2/KDR, IC50: 0.035 nM

{[allProObj[0].p_purity_real_show]}
Ki8751 ++++

VEGFR2, IC50: 0.9 nM

c-Kit {[allProObj[0].p_purity_real_show]}
SU 5402 ++

VEGFR2, IC50: 20 nM

{[allProObj[0].p_purity_real_show]}
Rivoceranib Mesylate ++++

VEGFR2, IC50: 1 nM

RET {[allProObj[0].p_purity_real_show]}
Ponatinib ++++

VEGFR2, IC50: 1.5 nM

{[allProObj[0].p_purity_real_show]}
LY2874455 +++

VEGFR2, IC50: 7 nM

{[allProObj[0].p_purity_real_show]}
ZM323881 HCl ++++

VEGFR2, IC50: <2 nM

{[allProObj[0].p_purity_real_show]}
AZD2932 +++

VEGFR-2, IC50: 8 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Cabozantinib ++++

VEGFR2/KDR, IC50: 0.035 nM

{[allProObj[0].p_purity_real_show]}
Sorafenib ++

VEGFR2/Flk1, IC50: 90 nM

VEGFR2, IC50: 90 nM

{[allProObj[0].p_purity_real_show]}
CYC-116 ++

VEGFR2, Ki: 44 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Golvatinib ++

VEGFR2, IC50: 16 nM

{[allProObj[0].p_purity_real_show]}
Sunitinib +

VEGFR2 , IC50: 80 nM

FLT3 {[allProObj[0].p_purity_real_show]}
RAF265 ++

VEGFR2, EC50: 30 nM

{[allProObj[0].p_purity_real_show]}
PD173074 {[allProObj[0].p_purity_real_show]}
BFH772 ++++

VEGFR2, IC50: 3 nM

{[allProObj[0].p_purity_real_show]}
Semaxinib +

VEGFR2/Flk1, IC50: 1.23 μM

{[allProObj[0].p_purity_real_show]}
Vandetanib ++

VEGFR2, IC50: 40 nM

+

VEGFR3, IC50: 110 nM

EGFR {[allProObj[0].p_purity_real_show]}
SAR131675 ++

VEGFR3, IC50: 23 nM

{[allProObj[0].p_purity_real_show]}
ENMD-2076 +

VEGFR2/KDR, IC50: 58.2 nM

++

VEGFR3/FLT4, IC50: 15.9 nM

FLT3,RET {[allProObj[0].p_purity_real_show]}
Telatinib +++

VEGFR2, IC50: 6 nM

++++

VEGFR3, IC50: 4 nM

c-Kit {[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 c-Kit 其他靶点 纯度
Tyrphostin AG1296 +

c-Kit (Swiss 3T3), IC50: 1.8 μM

PDGFR {[allProObj[0].p_purity_real_show]}
Masitinib +

Kit, IC50: 200 nM

{[allProObj[0].p_purity_real_show]}
Motesanib Diphosphate +++

Kit, IC50: 8 nM

{[allProObj[0].p_purity_real_show]}
Ki8751 ++

c-Kit, IC50: 40 nM

{[allProObj[0].p_purity_real_show]}
Tivozanib ++

c-Kit, IC50: 78 nM

{[allProObj[0].p_purity_real_show]}
Pazopanib +

c-Kit, IC50: 140 nM

{[allProObj[0].p_purity_real_show]}
Sitravatinib +++

Kit, IC50: 6 nM

{[allProObj[0].p_purity_real_show]}
Pexidartinib +++

Kit, IC50: 10 nM

{[allProObj[0].p_purity_real_show]}
Lactate ++++

c-Kit, IC50: 2 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Amuvatinib +++

c-Kit (D816H), IC50: 10 nM

{[allProObj[0].p_purity_real_show]}
Imatinib Mesylate +

c-Kit, IC50: 100 nM

PDGFR {[allProObj[0].p_purity_real_show]}
AZD2932 +++

c-Kit, IC50: 9 nM

{[allProObj[0].p_purity_real_show]}
Axitinib ++++

Kit, IC50: 1.7 nM

{[allProObj[0].p_purity_real_show]}
Dovitinib ++++

c-Kit, IC50: 2 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Sunitinib FLT3 {[allProObj[0].p_purity_real_show]}
OSI-930 +

Kit, IC50: 80 nM

{[allProObj[0].p_purity_real_show]}
Telatinib ++++

c-Kit, IC50: 1 nM

{[allProObj[0].p_purity_real_show]}
Dasatinib monohydrate ++

c-Kit (wt), IC50: 79 nM

c-Kit (D816V), IC50: 37 nM

Src {[allProObj[0].p_purity_real_show]}
Dasatinib ++

c-Kit (wt), IC50: 79 nM

c-Kit (D816V), IC50: 37 nM

Src {[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 PDGFR PDGFRα PDGFRβ 其他靶点 纯度
Tyrphostin A9 +

PDGFR, IC50: 0.5 μM

EGFR {[allProObj[0].p_purity_real_show]}
Tyrphostin AG1296 {[allProObj[0].p_purity_real_show]}
Motesanib Diphosphate ++

PDGFR, IC50: 84 nM

{[allProObj[0].p_purity_real_show]}
Pazopanib ++

PDGFR, IC50: 84 nM

{[allProObj[0].p_purity_real_show]}
Imatinib +

PDGFR, IC50: 100 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Imatinib Mesylate +

PDGFR, IC50: 100 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Sennoside B {[allProObj[0].p_purity_real_show]}
PP121 ++++

PDGFR, IC50: 2 nM

mTOR,VEGFR {[allProObj[0].p_purity_real_show]}
Crenolanib ++++

PDGFRα, Kd: 2.1 nM

++++

PDGFRβ, Kd: 3.2 nM

{[allProObj[0].p_purity_real_show]}
Masitinib +

PDGFRα, IC50: 540 nM

+

PDGFRβ, IC50: 800 nM

{[allProObj[0].p_purity_real_show]}
Ki8751 ++

PDGFRα, IC50: 67 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Tivozanib ++

PDGFRα, IC50: 40 nM

++

PDGFRβ, IC50: 49 nM

{[allProObj[0].p_purity_real_show]}
Ponatinib ++++

PDGFRα, IC50: 1.1 nM

{[allProObj[0].p_purity_real_show]}
Amuvatinib ++

PDGFRα (V561D), IC50: 40 nM

{[allProObj[0].p_purity_real_show]}
Axitinib +++

PDGFRα, IC50: 5.0 nM

++++

PDGFRβ, IC50: 1.6 nM

{[allProObj[0].p_purity_real_show]}
CP-673451 +++

PDGFRα, IC50: 10 nM

++++

PDGFRβ, IC50: 1 nM

{[allProObj[0].p_purity_real_show]}
Telatinib +++

PDGFRα, IC50: 15 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Nintedanib ++

PDGFRα, IC50: 59 nM

++

PDGFRβ, IC50: 65 nM

{[allProObj[0].p_purity_real_show]}
Avapritinib ++++

PDGFRα (D842V), IC50: 0.5 nM

{[allProObj[0].p_purity_real_show]}
MK-2461 +++

PDGFRβ, IC50: 22 nM

{[allProObj[0].p_purity_real_show]}
Lactate +++

PDGFRβ, IC50: 27 nM

c-Kit,FLT3 {[allProObj[0].p_purity_real_show]}
Linifanib ++

PDGFRβ, IC50: 66 nM

{[allProObj[0].p_purity_real_show]}
AZD2932 +++

PDGFRβ, IC50: 4 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Dovitinib +++

PDGFRβ, IC50: 27 nM

c-Kit,FLT3 {[allProObj[0].p_purity_real_show]}
Sorafenib ++

PDGFRβ, IC50: 57 nM

mPDGFRβ, IC50: 57 nM

{[allProObj[0].p_purity_real_show]}
Sunitinib ++++

PDGFRβ , IC50: 2 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Orantinib +++

PDGFRβ, Ki: 8 nM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 FGFR FGFR1 FGFR2 FGFR3 FGFR4 其他靶点 纯度
Tyrphostin AG1296 +

FGFR (Swiss 3T3), IC50: 12.3 μM

PDGFR {[allProObj[0].p_purity_real_show]}
Pazopanib +

FGFR, IC50: 140 nM

{[allProObj[0].p_purity_real_show]}
Erdafitinib RET {[allProObj[0].p_purity_real_show]}
Gambogenic acid {[allProObj[0].p_purity_real_show]}
Sulfatinib +++

FGFR1, IC50: 15 nM

{[allProObj[0].p_purity_real_show]}
Nintedanib esylate +

FGFR1, IC50: 69 nM

++

FGFR2, IC50: 37 nM

+

FGFR3, IC50: 108 nM

{[allProObj[0].p_purity_real_show]}
Zoligratinib +++

FGFR1, IC50: 9.3 nM

+++

FGFR2, IC50: 7.6 nM

++

FGFR3, IC50: 22 nM

+

FGFR4, IC50: 290 nM

{[allProObj[0].p_purity_real_show]}
MK-2461 +

FGFR1, IC50: 65 nM

++

FGFR2, IC50: 39 nM

++

FGFR3, IC50: 50 nM

{[allProObj[0].p_purity_real_show]}
SU 5402 ++

FGFR1, IC50: 30 nM

{[allProObj[0].p_purity_real_show]}
Brivanib +

FGFR1, IC50: 148 nM

{[allProObj[0].p_purity_real_show]}
Lucitanib ++

FGFR1, IC50: 17.5 nM

+

FGFR2, IC50: 82.5 nM

{[allProObj[0].p_purity_real_show]}
Ponatinib ++++

FGFR1, IC50: 2.2 nM

{[allProObj[0].p_purity_real_show]}
PD-166866 +

FGFR1, IC50: 52.4 nM

{[allProObj[0].p_purity_real_show]}
Narazaciclib ++

FGFR1, IC50: 26 nM

RET {[allProObj[0].p_purity_real_show]}
Lactate +++

FGFR1, IC50: 8 nM

+++

FGFR3, IC50: 9 nM

c-Kit,FLT3 {[allProObj[0].p_purity_real_show]}
Lenvatinib mesylate ++

FGFR1, IC50: 46 nM

c-RET {[allProObj[0].p_purity_real_show]}
LY2874455 ++++

FGFR1, IC50: 2.8 nM

++++

FGFR2, IC50: 2.6 nM

+++

FGFR3, IC50: 6.4 nM

+++

FGFR4, IC50: 6 nM

{[allProObj[0].p_purity_real_show]}
FIIN-2 +++

FGFR1, IC50: 3.09 nM

+++

FGFR2, IC50: 4.3 nM

++

FGFR3, IC50: 27 nM

++

FGFR4, IC50: 45.3 nM

{[allProObj[0].p_purity_real_show]}
FIIN-3 +++

FGFR1, IC50: 13.1 nM

++

FGFR2, IC50: 21 nM

++

FGFR3, IC50: 31.4 nM

++

FGFR4, IC50: 35.3 nM

{[allProObj[0].p_purity_real_show]}
Infigratinib ++++

FGFR1, IC50: 0.9 nM

++++

FGFR2, IC50: 1.4 nM

++++

FGFR3, IC50: 1.0 nM

FGFR3 (K650E), IC50: 4.9 nM

+

FGFR4, IC50: 60 nM

{[allProObj[0].p_purity_real_show]}
Danusertib ++

FGFR1, IC50: 47 nM

RET {[allProObj[0].p_purity_real_show]}
R1530 ++

FGFR1, IC50: 28 nM

{[allProObj[0].p_purity_real_show]}
ENMD-2076 +

FGFR1, IC50: 92.7 nM

+

FGFR2, IC50: 70.8 nM

FLT3,RET {[allProObj[0].p_purity_real_show]}
Dovitinib +++

FGFR1, IC50: 8 nM

+++

FGFR3, IC50: 9 nM

c-Kit,FLT3 {[allProObj[0].p_purity_real_show]}
Sorafenib +

FGFR1, IC50: 580 nM

{[allProObj[0].p_purity_real_show]}
SSR128129E +

FGFR1, IC50: 1.9 μM

{[allProObj[0].p_purity_real_show]}
AZD-4547 ++++

FGFR1, IC50: 0.2 nM

++++

FGFR2, IC50: 2.5 nM

++++

FGFR3, IC50: 1.8 nM

{[allProObj[0].p_purity_real_show]}
Lenvatinib ++

FGFR1, IC50: 46 nM

RET {[allProObj[0].p_purity_real_show]}
PD173074 ++

FGFR1, IC50: ~25 nM

{[allProObj[0].p_purity_real_show]}
S49076 ++

FGFR1, IC50: 18 nM

+++

FGFR2, IC50: 17 nM

+++

FGFR3, IC50: 15 nM

{[allProObj[0].p_purity_real_show]}
Futibatinib ++++

FGFR1, IC50: 1.8 nM

++++

FGFR2, IC50: 1.4 nM

++++

FGFR3, IC50: 1.6 nM

+++

FGFR4, IC50: 3.7 nM

{[allProObj[0].p_purity_real_show]}
Ferulic Acid +

FGFR1, IC50: 3.78 μM

+

FGFR2, IC50: 12.5 μM

{[allProObj[0].p_purity_real_show]}
Nintedanib +

FGFR1, IC50: 69 nM

++

FGFR2, IC50: 37 nM

+

FGFR3, IC50: 108 nM

+

FGFR4, IC50: 610 nM

{[allProObj[0].p_purity_real_show]}
ASP5878 ++++

FGFR1, IC50: 0.47 nM

++++

FGFR2, IC50: 0.6 nM

++++

FGFR3, IC50: 0.74 nM

+++

FGFR4, IC50: 3.5 nM

{[allProObj[0].p_purity_real_show]}
PRN1371 ++++

FGFR1, IC50: 0.6 nM

++++

FGFR2, IC50: 1.3 nM

+++

FGFR3, IC50: 4.1 nM

++

FGFR4, IC50: 19.3 nM

{[allProObj[0].p_purity_real_show]}
Derazantinib +++

FGFR1, IC50: 4.5 nM

++++

FGFR2, IC50: 1.8 nM

+++

FGFR3, IC50: 4.5 nM

++

FGFR4, IC50: 34 nM

RET {[allProObj[0].p_purity_real_show]}
ODM-203 +++

FGFR1, IC50: 11 nM

+++

FGFR2, IC50: 16 nM

+++

FGFR3, IC50: 6 nM

++

FGFR4, IC50: 35 nM

{[allProObj[0].p_purity_real_show]}
Pemigatinib ++++

FGFR1, IC50: 0.4 nM

++++

FGFR2, IC50: 0.5 nM

++++

FGFR3, IC50: 1.2 nM

++

FGFR4, IC50: 30 nM

{[allProObj[0].p_purity_real_show]}
SKLB 610 PDGFR {[allProObj[0].p_purity_real_show]}
Alofanib {[allProObj[0].p_purity_real_show]}
Lirafugratinib {[allProObj[0].p_purity_real_show]}
Masitinib mesylate FAK {[allProObj[0].p_purity_real_show]}
BLU9931 +

FGFR3, IC50: 150 nM

+++

FGFR4, IC50: 3 nM

{[allProObj[0].p_purity_real_show]}
BO-264 {[allProObj[0].p_purity_real_show]}
Fisogatinib +++

FGFR4, IC50: 5 nM

{[allProObj[0].p_purity_real_show]}
H3B-6527 ++++

FGFR4, IC50: <1.2 nM

{[allProObj[0].p_purity_real_show]}
Roblitinib ++++

FGFR4, IC50: 1.9 nM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

SU11652 生物活性

描述 SU11652 is a sunitinib analog with anti-tyrosine-kinase activity, also is identified as a potential inhibitor for Leishmania major (Lm) nucleoside diphosphate kinases NDK and structural studies indicated that this molecule binds to the active site of LmNDK in a similar conformation to nucleotides, mimicking natural substrates.

SU11652 参考文献

[1]Ellegaard AM, Groth-Pedersen L, et al. Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol Cancer Ther. 2013 Oct;12(10):2018-30.

[2]Guo Y, Chen Y, et al. SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J Hematol Oncol. 2012 Dec 6;5:72.

SU11652 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.05mL

2.41mL

1.21mL

24.10mL

4.82mL

2.41mL

SU11652 技术信息

CAS号326914-10-7
分子式C22H27ClN4O2
分子量 414.928
别名
运输蓝冰
存储条件

粉末

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 9 mg/mL(21.69 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。